NephroGenex Announces Research Collaborations For Pivotal Studies Of Pyridorin™ In Diabetic Nephropathy
Published: Mar 27, 2014
RESEARCH TRIANGLE PARK, N.C., March 27, 2014 (GLOBE NEWSWIRE) -- NephroGenex, Inc.(Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced collaborations with two leading research organizations to conduct the Company's Phase 3 PIONEER (PyrIdOriN in DiabEtic NEphRopathy) study.
Help employers find you! Check out all the jobs and post your resume.